<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncol Lett</journal-id><journal-id journal-id-type="iso-abbrev">Oncol Lett</journal-id><journal-id journal-id-type="publisher-id">OL</journal-id><journal-title-group><journal-title>Oncology Letters</journal-title></journal-title-group><issn pub-type="ppub">1792-1074</issn><issn pub-type="epub">1792-1082</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27123104</article-id><article-id pub-id-type="pmc">4840847</article-id><article-id pub-id-type="doi">10.3892/ol.2016.4414</article-id><article-id pub-id-type="publisher-id">OL-0-0-4414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>ZHANG</surname><given-names>TING</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-4414"/></contrib><contrib contrib-type="author"><name><surname>PAN</surname><given-names>QIONG</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-4414"/></contrib><contrib contrib-type="author"><name><surname>XIAO</surname><given-names>SONGSHU</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-4414"/></contrib><contrib contrib-type="author"><name><surname>LI</surname><given-names>LIJIE</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-4414"/></contrib><contrib contrib-type="author"><name><surname>XUE</surname><given-names>MIN</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-4414"/><xref rid="c1-ol-0-0-4414" ref-type="corresp"/></contrib></contrib-group><aff id="af1-ol-0-0-4414">Department of Obstetrics and Gynecology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China</aff><author-notes><corresp id="c1-ol-0-0-4414"><italic>Correspondence to</italic>: Dr Min Xue, Department of Obstetrics and Gynecology, The Third Xiangya Hospital of Central South University, 128 Tongzipo Road, Changsha, Hunan 410013, P.R. China, E-mail: <email>min_xue_1@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>05</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>05</day><month>4</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>11</volume><issue>5</issue><fpage>3287</fpage><lpage>3292</lpage><history><date date-type="received"><day>01</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>04</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Zhang et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>Ovarian cancer is a clinical type of gynecological malignant tumor with poor prognosis and a high mortality rate. At present, the primary treatment method used is surgery, with chemotherapy as an ajdunctive therapy. Thus, new short-term treatments should be identified. The aim of the present study was to investigate the short-term curative effects and safety of docetaxel combined with intraperitoneal cisplatin chemotherapy and hyperthermia treatment of advanced ovarian cancer. A total of 112 cases of advanced (stage III&#x02013;IV) ovarian cancer patients confirmed by clinical diagnosis between October 2014 and December 2015 were included in the study. The patients were randomly divided into the study and control groups (n=56 cases). The control group was treated with docetaxel and intraperitoneal cisplatin hyperthermic perfusion chemotherapy, while the study group was treated with docetaxel venous chemotherapy and intraperitoneal cisplatin cyclical hyperthermic perfusion chemotherapy with BR-TRG-1 body cavity hyperthermic perfusion treatment system. Clinical treatment results for short-term curative effects and adverse reactions were compared and analyzed 8 weeks after treatment. The total effective rate of the study and control groups were 87.5 and 62.5%, respectively, and the difference was statistically significant (P&#x0003c;0.05). The controlled rate of ascites, remission rate of tumor and descent rate of CA125 of patients in the study group were better than patients in the control group (P&#x0003c;0.05). The rate of adverse reactions of patients in the study group was 39.3%, and the grade of toxicity was from I to II, while the rate of adverse reactions of patients in the control group was 55.4%, and the grade of toxicity was from II to III. The difference between the two groups was statistically significant (P&#x0003c;0.05). In conclusion, applying the combination of docetaxel, intraperitoneal cisplatin hyperthermic perfusion chemotherapy and hyperthermia to treat advanced ovarian cancer can improve the curative effects with little toxicity; thus, it is worthy of promotion and application.</p></abstract><kwd-group><kwd>advanced ovarian cancer</kwd><kwd>docetaxel</kwd><kwd>intraperitoneal hyperthermic perfusion</kwd><kwd>chemotherapy</kwd><kwd>hyperthermia</kwd><kwd>combination therapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Ovarian cancer is a common clinical type of gynecological malignant tumor, with a poor prognosis and high mortality. Its concrete etiological factors are unknown, but may be associated with age, procreation, living environment, and emotional factors (<xref rid="b1-ol-0-0-4414" ref-type="bibr">1</xref>). In recent years, morbidity of ovarian cancer has been on the increase. At present, the main treatment method of ovarian cancer is surgery, but due to effusion in the patients' abdomen, which have biological behaviors of implantation and metastasis, chemotherapy is often used as an adjunctive therapy (<xref rid="b2-ol-0-0-4414" ref-type="bibr">2</xref>). When the patients of ovarian cancer seek medical assistance, the tumors are already at an advanced stage. The recurrence rate of patients who udnergo initial treatment is high, and the median survival time is approximately 1&#x02013;2 years after recurrence (<xref rid="b3-ol-0-0-4414" ref-type="bibr">3</xref>).</p><p>The present study aimed to examine the short-term curative effect and safety of combining docetaxel, a type of second-line agent in chemotherapy, as well as hyperthermic intraperitoneal perfusion with cisplatin and thermotherapy for the treatment of patients with advanced ovarian cancer. A total of 112 cases of patients with advanced (stage III&#x02013;IV) ovarian cancer were examined between October 2014 and December 2015 and comparisons were made of the results yielded.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title/><sec><title>Clinical information</title><p>One-hundred and twelve patients with advanced (stage III&#x02013;IV) ovarian cancer were admitted to the The Third Xiangya Hospital of Central South University between October 2014 and December 2015. Ovarian cancer was confirmed by clinical diagnosis. The patient age range was 32&#x02013;74 years, with an average age of 52.5&#x000b1;4.6 years. According to FIGO staging criteria, there were 70 cases of stage III, 42 cases of stage IV, 60 cases of serous adenocarcinoma, 22 cases of mucinous carcinoma, 16 cases of endometrioid adenocarcinoma and 14 cases of clear cell carcinoma.</p><p>The study subjects who were selected could not undergo surgery, or had recurrence of localized tumor after treatment. CA125 index was elevated, while the routine blood test and hepatic and renal function indices were normal. All 112 cases were confirmed by pathology. The patients were randomly divided into the study and control groups (n=56 cases per group). Patient characteristics of the two groups are shown in <xref rid="tI-ol-0-0-4414" ref-type="table">Table I</xref>.</p></sec><sec><title>Methods</title><p>A new method was used of combining docetaxel and hyperthermic intraperitoneal perfusion with cisplatin in the control group. Briefly, i) docetaxel venous chemotherapy: all 112 cases received 75 mg/m<sup>2</sup> docetaxel, injection of 5 mg dexamethasone (Beyotime Institute of Biotechnology, Shanghai, China) intravenously one day prior to chemotherapy, and administered dexamethasone, and palonosetron (Beyotime Institute of Biotechnology) 30 min prior to chemotherapy. This was followed by 30 mg docetaxel injectable powder in 100 ml 5% glucose as an intravenous drip and the patient was observed. If there was no paradoxical reaction, 500 ml 5% glucose was added into margin. Severe hypersensitivity reaction was then observed. During the process of intravenous drip, changes of the vital index were monitored closely; and ii) hyperthermic intraperitoneal perfusion with cisplatin: the manner in which abdominocentesis was carried out was dependent on the patient's weight. The patients of medium or lighter weight were punctured at the McBurney's point directly, while overweight or obese patients or who had ascites were given abdominal indwelling catheter and catheterization under the guidance of b-sonography when necessary. The patients with ascites were required to shed them as much as possible before peritoneal perfusion. Then, 60 mg cisplatin was added to 1,500-2,000 ml physiological saline, and the drip was quickly inserted into the abdominal cavity. The drip was fixed to ensure it was unobstructed, avoiding outleakage of medical liquid, and patient responses were observed. Patients were assisted to alternate posture following perfusion in order that the medical liquid mix sufficiently entered the abdominal cavity.</p><p>The combined docetaxel intraperitoneal chemotherapy and BR-TRG-I hyperthermic perfusion intraperitoneal treatment system was used to carry out hyperthermic intraperitoneal perfusion with cisplatin in the study group: i) Docetaxel intraperitoneal chemotherapy was performed in the same way as the control group; ii) BR-TRG-I hyperthermic perfusion intraperitoneal treatment system to carry out hyperthermic intraperitoneal perfusion with cisplatin: during the operation, four abdominal drain tubes were placed in the hepatic zones, spleen, left and right pelvic cavity, respectively. At the beginning of chemotherapy, the patients were in a supine position. Subsequently, 1,500 ml physiological saline and cisplatin were diluted in 500 ml physiological saline, and connect with BR-TRG-I hyperthermic perfusion intraperitoneal treatment system. Interfaces of the approach and outlet of external circulation were connected with two drain tubes, respectively. The outlet was closed and collateral circuIation was initiated. When the temperature reached 37&#x000b0;C, the valve of the outlet was opened, and when the temperature was steady at 43&#x000b0;C, cycles of perfusion were carried out for 60 min. Based on the flow speed of the ascites, the speed of the pumping fluid was adjusted in the abdominal cavity, and its general speed was 400&#x02013;500 ml/min. Perfusate (800&#x02013;1,000 ml) was left in the abdominal cavity after perfusion was finished. Cisplatin at a dose of 80&#x02013;100 mg/m<sup>2</sup>. Based on tolerance and drainage tube patency, the patients were divided equally into groups that had hyperthermic intraperitoneal perfusion 1&#x02013;3 times, once every other day.</p></sec><sec><title>Curative effect valuation standard</title><sec><title>Tumor responses</title><p>Evaluation standard of RECIST solid tumor was used to divide tumor responses of patients following treatment into validity and invalidity (<xref rid="b4-ol-0-0-4414" ref-type="bibr">4</xref>).</p></sec><sec><title>Control of ascites</title><p>According to the WHO evaluation criteria of clinical effects regarding non-measurable lesions of malignant tumor, we divided the levels of control ascites of patients following treatment into validity and invalidity (<xref rid="b5-ol-0-0-4414" ref-type="bibr">5</xref>).</p><p>According to changes of CA125 of patients after treatment, the clinical curative effects of patients were divided and discriminant criteria of prognosis into validity, stability and invalidity were considered (<xref rid="b6-ol-0-0-4414" ref-type="bibr">6</xref>).</p></sec><sec><title>Short-term curative effect</title><p>According to the standard evaluation of malignant tumors following treatment based on WHO, the short-term curative effects of patients in the present study were classified as complete remission, partial remission, stability and in progress. Complete remission and partial remission combined were judged as the total effective rate of short-term treatment (<xref rid="b7-ol-0-0-4414" ref-type="bibr">7</xref>).</p></sec><sec><title>Toxicity</title><p>The toxicological evaluation was performed according to grading criteria regarding the reaction of anticancer drugs established by WHO (<xref rid="b8-ol-0-0-4414" ref-type="bibr">8</xref>).</p></sec><sec><title>Adverse reaction</title><p>The occurrence of nausea, vomit, anemia, leukocytosis, neurotoxicity and other adverse reactions of patients was observed during treatment.</p></sec><sec><title>Statistical analysis</title><p>Data were statistically analyzed using using SPSS 21.0 software (IBM, Chicago, USA). Comparisons among groups were carried out using the Student's t-test. &#x003b1;=0.05 was a significant test level. P&#x0003c;0.05 indicated statistically significant results.</p></sec></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Comparisons of control of ascites, tumor responses and CA125 of patients in the two groups</title><p>Following treatment, the ascites control, tumor response and CA125 descent rates of patients in the study group were improved compared to the control group (P&#x0003c;0.05) (<xref rid="tII-ol-0-0-4414" ref-type="table">Table II</xref>).</p></sec><sec><title>Comparisons of short-term curative effect in the two groups</title><p>The total effective rate of the short-term treatment of patients in the study group was 87.5%, while that in the control group was 62.5%. Differences between the two groups were statistically significant (P&#x0003c;0.05) (<xref rid="tIII-ol-0-0-4414" ref-type="table">Table III</xref>).</p></sec><sec><title>Comparisons of toxicity and adverse reaction of patients in the two groups</title><p>The rate of nausea, vomit, anemia, leukopenia neurotoxicity and other adverse reactions in the study group was 39.3%, and the grade of toxicity was from grade I to grade II, while that of the control group was 55.4%, and grade of toxicity was from grade II to III. The differences between the two groups was statistically significant (P&#x0003c;0.05) (<xref rid="tIV-ol-0-0-4414" ref-type="table">Table IV</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Ovarian cancer is a type of gynecological malignant tumor with a high mortality rate (<xref rid="b1-ol-0-0-4414" ref-type="bibr">1</xref>). As the disease does not exhibit specific clinical manifestations, most patients may be at an advanced stage (III to IV) when symptoms become evident leading to loss of treatment time. Thus, the rate of successful treatment is extremely low and only palliative chemotherapy may be utilized to control conditions, relieve or improve patient symptoms, promote life quality as much as possible and prolong survival times.</p><p>For advanced ovarian cancer, the standard treatment clinically remains carcinoma cytoreductive surgery followed by intraperitoneal chemotherapy with a combinatorial treatment of platinum and paclitaxel (<xref rid="b3-ol-0-0-4414" ref-type="bibr">3</xref>).</p><p>However, not all patients with advanced ovarian cancer achieve satisfactory clinical results following cytoreductive surgery, and most patients have poor long-term curative effect. Previous studies have shown that dissemination and transfer of ovarian cancer which occur easily are usually biological characteristics that are limited in the abdominopelvic cavity of patients (<xref rid="b9-ol-0-0-4414" ref-type="bibr">9</xref>). Consequently, intraperitoneal chemotherapy has gradually become a therapeutic approach that is favored by patients with advanced ovarian cancer.</p><p>Docetaxel is a type of first-line chemotherapeutic agent that has become widely used. The mechanisms of docetaxel in the treatment of tumors involve the enhancement of tubulin polymerization with the simultaneous inhibition of microtubule depolymerization, and the formation of stable non-functional microtubules that obstruct tumor cell mitosis, leading to an antitumor effect (<xref rid="b10-ol-0-0-4414" ref-type="bibr">10</xref>).</p><p>Previous findings have shown that the concentration of docetaxel is 3-fold that of paclitaxel in tumor cells, and lasts a longer period of time as compared to paclitaxel (<xref rid="b10-ol-0-0-4414" ref-type="bibr">10</xref>). Thus, compared to paclitaxel, docetaxel has a higher antitumor activity. In addition, the total effective rate for treating ovarian cancer is 73% when using 75 mg/m<sup>2</sup> docetaxel and carboplatin with AUC of 5, and the median survival time of patients following treatment is 18 months, while the overall survival time reaches 24.2 months (<xref rid="b11-ol-0-0-4414" ref-type="bibr">11</xref>). In a study by Di&#x000e9;ras <italic>et al</italic>, patients with advanced ovarian cancer (stage III to IV) underwent cytoreductive surgery, and were administered chemotherapy using 75 mg/m<sup>2</sup> docetaxel and 75 mg/m<sup>2</sup> carboplatin, leading to a total effective rate of 58% (<xref rid="b12-ol-0-0-4414" ref-type="bibr">12</xref>). Thus, docetaxel and carboplatin are effective in the treatment of advanced ovarian cancer and can be used as first-line treatment in clinical chemotherapy of patients with advanced ovarian cancer.</p><p>The treatment effect of abdominal malignant tumor is closely associated with peritoneal metastasis. By controlling peritoneal metastasis, the long-term survival rate of patients can be prolonged and their quality of life can be improved effectively (<xref rid="b13-ol-0-0-4414" ref-type="bibr">13</xref>). How to control the peritoneal metastasis of patients with abdominal malignant tumor effectively is an important issue, and a challenge regarding the clinical treatment of tumor. In addition, intraperitoneal hyperthermic perfusion chemotherapy is applied after abdominal cavity malignant tumor surgery, which eliminates the subclinical lesions of patients following treatment, removes malignant ascites effectively and prolongs the 5-year survival of patients with advanced ovarian and gastric cancer, which may lead to abdominal cavity implantation metastasis (<xref rid="b14-ol-0-0-4414" ref-type="bibr">14</xref>). The effective rate of the clinical treatment of malignant ascites can reach 90%.</p><p>The clinical application and promotion of intraperitoneal hyperthermic perfusion chemotherapy has been employed in certain medical institutions in America and Spain, France, Italy and Britain as the standard treatment clinically for abdomen malignant tumor. Australia has also promoted the development of intraperitoneal hyperthermic perfusion chemotherapy (<xref rid="b15-ol-0-0-4414" ref-type="bibr">15</xref>&#x02013;<xref rid="b17-ol-0-0-4414" ref-type="bibr">17</xref>).</p><p>In China intraperitoneal hyperthermic perfusion chemotherapy has been used in the treatment of abdomen malignant tumor as well as advanced ovarian cancer (since 2004), with good results (<xref rid="b18-ol-0-0-4414" ref-type="bibr">18</xref>). The present findings have shown that the total effective rate of patients with advanced ovarian cancer in the study group was 87.5%, while that in the control group was 62.5%. The differences between the two groups were statistically significant (P&#x0003c;0.05).</p><p>In general, medical therapy units in China that carry out intraperitoneal hyperthermic perfusion chemotherapy are in the primary stage, medical technology requires improvement, manufacturing technology of medical equipment is difficult, accuracy of temperature control is not high, and perfusion speed of peritoneal cavity fluid is not steady, making it difficult to achieve optimal curative effect of intraperitoneal hyperthermic perfusion chemotherapy (<xref rid="b18-ol-0-0-4414" ref-type="bibr">18</xref>). The BR-TRG-I hyperthermic perfusion intraperitoneal treatment system, used by our hospital, has high accuracy, its temperature measurement accuracy and temperature controlling precision can reach &#x000b1;0.1 and &#x000b1;0.2&#x000b0;C, respectively, and perfusion speed is more stable, and is within 5% accuracy. It is arguable that automatic control technique of this system is comparable to an international advanced level and can provide good protection insurance of medical equipment for patients with advanced ovarian cancer (<xref rid="b18-ol-0-0-4414" ref-type="bibr">18</xref>).</p><p>Localized temperature a patient's abdominal cavity can reach 43&#x000b0;C following treatment of intraperitoneal hyperthermic perfusion chemotherapy. Tumor cells are damaged irreversibly under conditions of high temperatures (43&#x000b0;C) that last 1 h (<xref rid="b18-ol-0-0-4414" ref-type="bibr">18</xref>). After heating, the pH value of tumor tissues may decrease, leading to dyspoiesis of nucleic acid <italic>in vivo</italic>, which promotes tumor cell apoptosis. However, normal tissues of the human body are not affected by high temperatures of 43&#x000b0;C. Generally, normal tissues can tolerate high temperature conditions of 47&#x000b0;C for &#x0003e;1 h (<xref rid="b19-ol-0-0-4414" ref-type="bibr">19</xref>).</p><p>Thus, intraperitoneal hyperthermic perfusion chemotherapy can kill cancer cells selectively, but does not affect normal tissues of the human body. Compared with traditional intravenous chemotherapy, the administration route of intraperitoneal chemotherapy also improves the concentration of anticarcinogens in the abdominal cavity and improves the time of direct reaction between anticarcinogens and tumor cells (<xref rid="b18-ol-0-0-4414" ref-type="bibr">18</xref>). At the same time, because anticarcinogen reflows to the hepatic system through the portal vein system and enters the systemic circulation after hepatic metabolism, it has few systemic side effects for patients.</p><p>Cisplatin belongs to typical drugs of intraperitoneal chemotherapy and clinical antitumor drugs of first-generation platinum (<xref rid="b12-ol-0-0-4414" ref-type="bibr">12</xref>). This drug mainly acts on purines and the pyrimidine base of DNA in the human body. It can constitute the interlocking of intrachain and interchain DNA in human body which damages DNA functions, obstructs DNA replication and inhibits DNA to synthesize effectively. A high concentration of cisplatin can also obstruct synthesis of RNA and protein (<xref rid="b12-ol-0-0-4414" ref-type="bibr">12</xref>). Effective concentration of cisplatin in the human body has a lasting effect, and can be maintain over a long period of time <italic>in vivo</italic> (<xref rid="b12-ol-0-0-4414" ref-type="bibr">12</xref>). It has difficulty of passing the barrier of peritoneum, thus, the concentration of cisplatin in peritoneum is higher than that of plasma.</p><p>Cisplatin is a type of antineoplastic clinical drug without threshold effect (<xref rid="b20-ol-0-0-4414" ref-type="bibr">20</xref>). Heat treatment can promote the combination of DNA of human cells and cisplatin, which allows the concentration of cisplatin reaching tumor cells to increase and inhibits the restoration of cells to themselves after cisplatin drug acts on the tumor cells.</p><p>A combination of cisplatin and heat treatment has synergistic effects. Thus, cisplatin is an optimal anticancer drug for intraperitoneal hyperthermic perfusion (<xref rid="b12-ol-0-0-4414" ref-type="bibr">12</xref>). The present study used cisplatin as an anticancer drug for intraperitoneal hyperthermic perfusion. The results obtained showed that the rate of adverse reactions in the study group was 39.3% and the grade of toxicity was from grade I to II, while the rate of adverse reactions in the control group was 55.4% and the grade of toxicity was from II to III. The differences between the two groups were statistically significant (P&#x0003c;0.05). Thus, a combination of docetaxel intraperitoneal chemotherapy and BR-TRG-I hyperthermic perfusion intraperitoneal treatment system to carry out hyperthermic intraperitoneal perfusion with cisplatin while treating patients with advanced ovarian cancer has low toxicity and little adverse reactions.</p><p>Malignant ascites is a common and main complication of patients with advanced ovarian cancer. Once this complication occurs, it induces renal failure, leading to blockage of cardiopulmonary functions, seriously affecting survival and quality of life for patients, which deteriorates the conditions of patients to a large extent (<xref rid="b15-ol-0-0-4414" ref-type="bibr">15</xref>).</p><p>The majority of treatments for malignant effusion involved repeated paracentesis. Although this treatment rapidly relieves the symptoms of patients, ascites in the abdominal cavity gather together rapidly and form a vicious circle, which leads to ineffective treatment and accelerates mortality (<xref rid="b15-ol-0-0-4414" ref-type="bibr">15</xref>).</p><p>Use of BR-TRG-I hyperthermic perfusion intraperitoneal treatment system to carry out hyperthermic intraperitoneal perfusion with cisplatin while treating, which can effectively reduce the accumulation of ascites in the abdominal cavity of patients, resulting in the treatment of malignant ascites is considerable. The control rate of hydrothorax and ascites can be improved by hyperthermic perfusion and the control level can reach 80% (<xref rid="b21-ol-0-0-4414" ref-type="bibr">21</xref>). The results of the present study have shown that the ascites control and tumor response rates in the study group were improved as compared to the control group (P&#x0003c;0.05), confirming that it is effective and practical to utilize BR-TRG-I hyperthermic perfusion intraperitoneal treatment system to carry out hyperthermic intraperitoneal perfusion with cisplatin while treating patients with advanced ovarian cancer accompanied with ascites.</p><p>CA125 belongs to the glycoprotein antigens. It is an important ovarian cancer-associated antigen used to diagnose ovarian cancer and evaluate the clinical effects of ovarian cancer (<xref rid="b22-ol-0-0-4414" ref-type="bibr">22</xref>). Our findings have shown that the CA125 descent rate of patients in the study group was better than that of the control group (P&#x0003c;0.05). Thus, use of BR-TRG-I hyperthermic perfusion intraperitoneal treatment system to carry out hyperthermic intraperitoneal perfusion with cisplatin while treating patietns with advanced ovarian cancer can decrease level of CA125 effectively.</p><p>In conclusion, the combination of docetaxel, hyperthermic intraperitoneal perfusion with cisplatin and thermotherapy while treating patients with advanced ovarian cancer clinically can improve the short-term curative effect of patients and relief toxicity of patients. Clinically, patients can be administered hyperthermic perfusion 1&#x02013;3 times for each treatment, and increased treatment times indicate that the short-term curative effect of advanced ovarian cancer is likely to be improved. Since 2014, our hospital has employed intraperitoneal hyperthermic perfusion chemotherapy to carry out hyperthermic intraperitoneal perfusion with cisplatin. The results suggest that 3- and 5-year survival time of the subjects require follow-up observation. A limitation of the study was that the sample size was small. Thus, large-scale investigations are needed to conduct prospective clinical studies to verify the results obtained in the present study.</p></sec></body><back><ref-list><title>References</title><ref id="b1-ol-0-0-4414"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyashiro</surname><given-names>I</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Sasako</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Nashimoto</surname><given-names>A</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>O</given-names></name><name><surname>Arai</surname><given-names>K</given-names></name></person-group><article-title>Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group: Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2</article-title><source>Gastric Cancer</source><volume>14</volume><fpage>212</fpage><lpage>218</lpage><year>2011</year><pub-id pub-id-type="doi">10.1007/s10120-011-0027-3</pub-id><pub-id pub-id-type="pmid">21336855</pub-id></element-citation></ref><ref id="b2-ol-0-0-4414"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emoto</surname><given-names>S</given-names></name><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Ishigami</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name></person-group><article-title>Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination</article-title><source>Ann Surg Oncol</source><volume>22</volume><fpage>780</fpage><lpage>786</lpage><year>2015</year><pub-id pub-id-type="doi">10.1245/s10434-014-4082-y</pub-id><pub-id pub-id-type="pmid">25216603</pub-id></element-citation></ref><ref id="b3-ol-0-0-4414"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>TC</given-names></name><name><surname>Morris</surname><given-names>DL</given-names></name><name><surname>Saxena</surname><given-names>A</given-names></name><name><surname>Esquivel</surname><given-names>J</given-names></name><name><surname>Liauw</surname><given-names>W</given-names></name><name><surname>Doerfer</surname><given-names>J</given-names></name><name><surname>Germer</surname><given-names>CT</given-names></name><name><surname>Kerscher</surname><given-names>AG</given-names></name><name><surname>Pelz</surname><given-names>JO</given-names></name></person-group><article-title>Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study</article-title><source>Ann Surg Oncol</source><volume>18</volume><fpage>1560</fpage><lpage>1567</lpage><year>2011</year><pub-id pub-id-type="doi">10.1245/s10434-010-1522-1</pub-id><pub-id pub-id-type="pmid">21203904</pub-id></element-citation></ref><ref id="b4-ol-0-0-4414"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>D</given-names></name><name><surname>Gilly</surname><given-names>F</given-names></name><name><surname>Boutitie</surname><given-names>F</given-names></name><name><surname>Quenet</surname><given-names>F</given-names></name><name><surname>Bereder</surname><given-names>JM</given-names></name><name><surname>Mansvelt</surname><given-names>B</given-names></name><name><surname>Lorimier</surname><given-names>G</given-names></name><name><surname>Dub&#x000e8;</surname><given-names>P</given-names></name><name><surname>Glehen</surname><given-names>O</given-names></name></person-group><article-title>Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study</article-title><source>J Clin Oncol</source><volume>28</volume><fpage>63</fpage><lpage>68</lpage><year>2010</year><pub-id pub-id-type="doi">10.1200/JCO.2009.23.9285</pub-id><pub-id pub-id-type="pmid">19917863</pub-id></element-citation></ref><ref id="b5-ol-0-0-4414"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishigami</surname><given-names>H</given-names></name><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Kaisaki</surname><given-names>S</given-names></name><name><surname>Hidemura</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Otani</surname><given-names>K</given-names></name><name><surname>Kamei</surname><given-names>T</given-names></name><name><surname>Soma</surname><given-names>D</given-names></name><name><surname>Miyato</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><etal/></person-group><article-title>Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis</article-title><source>Ann Oncol</source><volume>21</volume><fpage>67</fpage><lpage>70</lpage><year>2010</year><pub-id pub-id-type="doi">10.1093/annonc/mdp260</pub-id><pub-id pub-id-type="pmid">19605503</pub-id></element-citation></ref><ref id="b6-ol-0-0-4414"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>D</given-names></name><name><surname>Glehen</surname><given-names>O</given-names></name><name><surname>Pocard</surname><given-names>M</given-names></name><name><surname>Quenet</surname><given-names>F</given-names></name><name><surname>Go&#x000e9;r&#x000e9;</surname><given-names>D</given-names></name><name><surname>Arvieux</surname><given-names>C</given-names></name><name><surname>Rat</surname><given-names>P</given-names></name><name><surname>Gilly</surname><given-names>F</given-names></name></person-group><article-title>Association Fran&#x000e7;aise de Chirurgie: A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix</article-title><source>Ann Surg</source><volume>251</volume><fpage>896</fpage><lpage>901</lpage><year>2010</year><pub-id pub-id-type="doi">10.1097/SLA.0b013e3181d9765d</pub-id><pub-id pub-id-type="pmid">20395843</pub-id></element-citation></ref><ref id="b7-ol-0-0-4414"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Huang</surname><given-names>CQ</given-names></name><name><surname>Suo</surname><given-names>T</given-names></name><name><surname>Mei</surname><given-names>LJ</given-names></name><name><surname>Yang</surname><given-names>GL</given-names></name><name><surname>Cheng</surname><given-names>FL</given-names></name><name><surname>Zhou</surname><given-names>YF</given-names></name><name><surname>Xiong</surname><given-names>B</given-names></name><name><surname>Yonemura</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial</article-title><source>Ann Surg Oncol</source><volume>18</volume><fpage>1575</fpage><lpage>1581</lpage><year>2011</year><pub-id pub-id-type="doi">10.1245/s10434-011-1631-5</pub-id><pub-id pub-id-type="pmid">21431408</pub-id></element-citation></ref><ref id="b8-ol-0-0-4414"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapala</surname><given-names>M</given-names></name><name><surname>Meterissian</surname><given-names>S</given-names></name><name><surname>Schricker</surname><given-names>T</given-names></name></person-group><article-title>Neuraxial anesthesia and intraoperative bilevel positive airway pressure in a patient with severe chronic obstructive pulmonary disease and obstructive sleep apnea undergoing elective sigmoid resection</article-title><source>Reg Anesth Pain Med</source><volume>34</volume><fpage>69</fpage><lpage>71</lpage><year>2009</year><pub-id pub-id-type="doi">10.1097/AAP.0b013e31819266b2</pub-id><pub-id pub-id-type="pmid">19258991</pub-id></element-citation></ref><ref id="b9-ol-0-0-4414"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>TC</given-names></name><name><surname>Morris</surname><given-names>DL</given-names></name><name><surname>Esquivel</surname><given-names>J</given-names></name></person-group><article-title>Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy</article-title><source>Ann Surg Oncol</source><volume>17</volume><fpage>1330</fpage><lpage>1336</lpage><year>2010</year><pub-id pub-id-type="doi">10.1245/s10434-009-0866-x</pub-id><pub-id pub-id-type="pmid">20033321</pub-id></element-citation></ref><ref id="b10-ol-0-0-4414"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Ishigami</surname><given-names>H</given-names></name><name><surname>Emoto</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name></person-group><article-title>A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis</article-title><source>Cancer</source><volume>119</volume><fpage>3354</fpage><lpage>3358</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/cncr.28204</pub-id><pub-id pub-id-type="pmid">23798046</pub-id></element-citation></ref><ref id="b11-ol-0-0-4414"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franko</surname><given-names>J</given-names></name><name><surname>Ibrahim</surname><given-names>Z</given-names></name><name><surname>Gusani</surname><given-names>NJ</given-names></name><name><surname>Holtzman</surname><given-names>MP</given-names></name><name><surname>Bartlett</surname><given-names>DL</given-names></name><name><surname>Zeh</surname><given-names>HJ</given-names><suffix>III</suffix></name></person-group><article-title>Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis</article-title><source>Cancer</source><volume>116</volume><fpage>3756</fpage><lpage>3762</lpage><year>2010</year><pub-id pub-id-type="doi">10.1002/cncr.25116</pub-id><pub-id pub-id-type="pmid">20564081</pub-id></element-citation></ref><ref id="b12-ol-0-0-4414"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di&#x000e9;ras</surname><given-names>V</given-names></name><name><surname>Guastalla</surname><given-names>JP</given-names></name><name><surname>Ferrero</surname><given-names>JM</given-names></name><name><surname>Cur&#x000e9;</surname><given-names>H</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Winckel</surname><given-names>P</given-names></name><name><surname>Lortholary</surname><given-names>A</given-names></name><name><surname>Mayer</surname><given-names>F</given-names></name><name><surname>Paraiso</surname><given-names>D</given-names></name><name><surname>Magherini</surname><given-names>E</given-names></name><etal/></person-group><article-title>A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: A GINECO study</article-title><source>Cancer Chemother Pharmacol</source><volume>53</volume><fpage>489</fpage><lpage>495</lpage><year>2004</year><pub-id pub-id-type="doi">10.1007/s00280-004-0762-9</pub-id><pub-id pub-id-type="pmid">14767617</pub-id></element-citation></ref><ref id="b13-ol-0-0-4414"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Ishigami</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name></person-group><article-title>Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) combined with oral tegafur/gimeracil/oteracil potassium (S-1) for gastric cancer with peritoneal metastasis</article-title><source>Eur J Surg Oncol</source><volume>40</volume><fpage>S34</fpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.ejso.2014.08.064</pub-id></element-citation></ref><ref id="b14-ol-0-0-4414"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AW</given-names></name><name><surname>Tyrer</surname><given-names>JP</given-names></name><name><surname>Doherty</surname><given-names>JA</given-names></name><name><surname>Stram</surname><given-names>DA</given-names></name><name><surname>Kupryjanczyk</surname><given-names>J</given-names></name><name><surname>Dansonka-Mieszkowska</surname><given-names>A</given-names></name><name><surname>Plisiecka-Halasa</surname><given-names>J</given-names></name><name><surname>Spiewankiewicz</surname><given-names>B</given-names></name><name><surname>Myers</surname><given-names>EJ</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><etal/></person-group><article-title>Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group: Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study</article-title><source>Gynecol Oncol</source><volume>136</volume><fpage>542</fpage><lpage>548</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ygyno.2014.12.017</pub-id><pub-id pub-id-type="pmid">25528498</pub-id></element-citation></ref><ref id="b15-ol-0-0-4414"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Che</surname><given-names>YL</given-names></name><name><surname>Luo</surname><given-names>SJ</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>YM</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Dai</surname><given-names>JM</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasis</article-title><source>Cancer Lett</source><volume>359</volume><fpage>241</fpage><lpage>249</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.canlet.2015.01.019</pub-id><pub-id pub-id-type="pmid">25617801</pub-id></element-citation></ref><ref id="b16-ol-0-0-4414"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>SW</given-names></name><name><surname>Marrache</surname><given-names>S</given-names></name><name><surname>Cummins</surname><given-names>S</given-names></name><name><surname>Bhutia</surname><given-names>YD</given-names></name><name><surname>Mody</surname><given-names>H</given-names></name><name><surname>Hooks</surname><given-names>SB</given-names></name><name><surname>Dhar</surname><given-names>S</given-names></name><name><surname>Govindarajan</surname><given-names>R</given-names></name></person-group><article-title>Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach</article-title><source>Cancer Lett</source><volume>359</volume><fpage>233</fpage><lpage>240</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.canlet.2015.01.017</pub-id><pub-id pub-id-type="pmid">25600708</pub-id></element-citation></ref><ref id="b17-ol-0-0-4414"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name></person-group><article-title>Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells</article-title><source>Biochim Biophys Acta</source><volume>1852</volume><fpage>395</fpage><lpage>405</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bbadis.2014.12.002</pub-id><pub-id pub-id-type="pmid">25483711</pub-id></element-citation></ref><ref id="b18-ol-0-0-4414"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakrin</surname><given-names>N</given-names></name><name><surname>Classe</surname><given-names>JM</given-names></name><name><surname>Pomel</surname><given-names>C</given-names></name><name><surname>Gouy</surname><given-names>S</given-names></name><name><surname>Chene</surname><given-names>G</given-names></name><name><surname>Glehen</surname><given-names>O</given-names></name></person-group><article-title>Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer</article-title><source>J Visc Surg</source><volume>151</volume><fpage>347</fpage><lpage>353</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.jviscsurg.2014.07.005</pub-id><pub-id pub-id-type="pmid">25168575</pub-id></element-citation></ref><ref id="b19-ol-0-0-4414"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helm</surname><given-names>CW</given-names></name></person-group><article-title>Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer</article-title><source>Surg Oncol Clin N Am</source><volume>21</volume><fpage>645</fpage><lpage>663</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.soc.2012.07.007</pub-id><pub-id pub-id-type="pmid">23021722</pub-id></element-citation></ref><ref id="b20-ol-0-0-4414"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="editor"><name><surname>Parson</surname><given-names>EN</given-names></name><name><surname>Lentz</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>G</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name><name><surname>Levine</surname><given-names>EA</given-names></name><name><surname>Stewart</surname><given-names>JH</given-names><suffix>IV</suffix></name></person-group><article-title>Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms</article-title><source>Am J Surg</source><volume>202</volume><fpage>481</fpage><lpage>486</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.amjsurg.2011.02.004</pub-id><pub-id pub-id-type="pmid">21474115</pub-id></element-citation></ref><ref id="b21-ol-0-0-4414"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohashi</surname><given-names>N</given-names></name><name><surname>Jinno</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>D</given-names></name><name><surname>Tanaka</surname><given-names>C</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Nomoto</surname><given-names>S</given-names></name><name><surname>Fujiwara</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Kodera</surname><given-names>Y</given-names></name></person-group><article-title>Intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis</article-title><source>Nihon Shokaki Geka Gakkai Zasshi</source><volume>45</volume><fpage>1137</fpage><lpage>1143</lpage><year>2012</year><comment>(In Japanese)</comment><pub-id pub-id-type="doi">10.5833/jjgs.45.1137</pub-id></element-citation></ref><ref id="b22-ol-0-0-4414"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Lis</surname><given-names>CG</given-names></name></person-group><article-title>Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature</article-title><source>J Ovarian Res</source><volume>2</volume><fpage>13</fpage><year>2009</year><pub-id pub-id-type="doi">10.1186/1757-2215-2-13</pub-id><pub-id pub-id-type="pmid">19818123</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-ol-0-0-4414" orientation="portrait" position="float"><label>Table I.</label><caption><p>Patient characteristics of the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Study group (n=56)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control group (n=56)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Staging criteria of FIGO</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage III</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage IV</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">21</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pathology</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Serous adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mucinous carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Endometrioid adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Clear-cell carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ascites</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;No</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CA125</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Increase</td><td align="center" valign="top" rowspan="1" colspan="1">53</td><td align="center" valign="top" rowspan="1" colspan="1">52</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Normal</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Localized tumor</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;No</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">25</td></tr></tbody></table></table-wrap><table-wrap id="tII-ol-0-0-4414" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparisons of control of ascites, tumor responses and CA125 of patients in the two groups [case (%)].</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">Study group</th><th align="center" valign="bottom" colspan="2" rowspan="1">Control group</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th rowspan="1" colspan="1"/></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Index</th><th align="center" valign="bottom" rowspan="1" colspan="1">Effective cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Effective rate</th><th align="center" valign="bottom" rowspan="1" colspan="1">Effective cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Effective rate</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Ascites controlled rate</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">21/27 (77.8)</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">17/29 (58.6)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor response rate</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">22/30 (73.3)</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">14/31 (45.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CA125 descent rate</td><td align="center" valign="top" rowspan="1" colspan="1">45</td><td align="center" valign="top" rowspan="1" colspan="1">45/53 (84.9)</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">33/52 (63.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap><table-wrap id="tIII-ol-0-0-4414" orientation="portrait" position="float"><label>Table III.</label><caption><p>Comparisons of short-term curative effect in the two groups [case (%)].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Complete remission</th><th align="center" valign="bottom" rowspan="1" colspan="1">Partial remission</th><th align="center" valign="bottom" rowspan="1" colspan="1">Stability</th><th align="center" valign="bottom" rowspan="1" colspan="1">In progress</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total effective rate</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Study (n=56)</td><td align="center" valign="top" rowspan="1" colspan="1">33 (58.9)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (5.4)</td><td align="center" valign="top" rowspan="1" colspan="1">49 (87.5)<sup><xref rid="tfn1-ol-0-0-4414" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control (n=56)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (37.5)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (25)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (21.4)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (16.1)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (62.5)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ol-0-0-4414"><label>a</label><p>Compared with control group, P&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-ol-0-0-4414" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Comparisons of toxicity and adverse reaction of patients in the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Grade of toxicity</th><th align="center" valign="bottom" rowspan="1" colspan="1">Nausea/vomit n (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Anemia n (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Leukopenia n (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Neurotoxicity n (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total adverse reaction rate, n (%)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Study (n=56)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;0</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;I</td><td align="left" valign="top" rowspan="1" colspan="1">3 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (10.7)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (1.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;II</td><td align="left" valign="top" rowspan="1" colspan="1">4 (7.1)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;IV</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">7 (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (16.1)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (8.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (1.8)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (39.3)<sup><xref rid="tfn2-ol-0-0-4414" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control (n=56)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;0</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;I</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;II</td><td align="left" valign="top" rowspan="1" colspan="1">2 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (5.4)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (17.9)</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td><td align="left" valign="top" rowspan="1" colspan="1">5 (8.9)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (10.7)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (10.7)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (37.5)</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;IV</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">7 (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (14.3)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (16.1)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (12.5)</td><td align="center" valign="top" rowspan="1" colspan="1">31 (55.4)</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-ol-0-0-4414"><label>a</label><p>Compared with control group, P&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></article>